服用厄达替尼的禁忌和注意事项

In April 2019, the first targeted drug for bladder cancer was finally approved for marketing in the United States. Since then, bladder cancer has entered the era of precision treatment.

Contraindications for taking erdafitinib: It is contraindicated in patients who are allergic to erdafitinib and its drug ingredients and pregnant women.

Precautions for erdafitinib:

1. Hyperphosphatemia

Serum phosphate exceeded the upper limit of normal in 76% of patients taking erdafitinib, with a median onset of 20 days. Phosphate-lowering drugs were required in 32% of patients. If the patient's serum phosphate exceeds 5.5 mg/dL, the drug dosage regimen should be adjusted.

2. Eye diseases

Erdafitinib can cause central serous retinopathy or retinal pigment epithelial detachment, with clinical symptoms such as blurred vision, visual floaters, or visual fatigue. The incidence rate is 25% (Grade 3, 3%). The median onset time is 50 days. 13% of patients are relieved, and 13% of patients still suffer from the disease by the clinical cutoff. Erdafitinib was suspended in 9% of patients, reduced in 14% of patients, and permanently discontinued in 3% of patients.

Dry eye syndrome occurs in 28% (grade 3, 6%), use eye drops if necessary.

Have an eye examination, including optical coherence tomography (OCT), before taking erdafitinib, every 1 month for the first 4 months of taking the drug, and every 3 months after 4 months. If you notice visual symptoms, see your doctor right away and follow up every three weeks until symptoms subside.

3. Embryo-fetal toxicity

Animal tests show embryo-fetal toxicity. Patients and partners should use effective contraception while taking the drug and within one month after stopping the drug.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: